Medical Therapy. Adverse Effects or Lack of Adverse Effects

Descriptive study of the effects of treprostinil and/or epoprostenol in newborn infants with inhaled NO refractory persistent pulmonary hypertension of the newborn (PPHN)

Charlotte Mazepa, Sébastien Mur, Géraldine Gascoind, Laurent Storme, Nicolas Joram, Caroline Viard, Yves Dulac, Marine Butini, Sophie BreinigChildren’s Hospital, CHU de Toulouse and Université de Toulouse. Lille University Hospital. Jeanne-de-Flandre Hospital and CHU de Lille. Nantes University Hospital. Hôpital Femme-Mère-Enfant, Hospices civils de Lyon and Université Claude-Bernard-Lyon. France TherapeuticsTherapie 2026; DOI: 10.1016/j.therap.2026.03.001 AbstractBackground: Epoprostenol and treprostinil, prostacyclin […]

Descriptive study of the effects of treprostinil and/or epoprostenol in newborn infants with inhaled NO refractory persistent pulmonary hypertension of the newborn (PPHN) Read More »

Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial

Wesley M. Jackson, Henry P. Foote, Nicole Stephenson, Steven M. Kemp, Ryan T. Moore, Christopher R. Nitkin, Dan Stewart, Gloria S. Pryhuber, John T. Berger, Ankita Shukla, Amand England, Stephanie M. Ford, Lance A. Parton, Jennifer F. Check, Mina H. Hanna, Megan Lagoski, Ramesh Krishnan, Kristen T. Leeman, Shilpa Vyas-Read, Mark L. Hudak, Anup C.

Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial Read More »

Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children

Meng Li, Yingchun Wang, Xiaoyu Hu, Haizhao Zhao, Weida Lu, Yuan Ji, Xiaopei CuiQilu Hospital and Cheeloo College of Medicine of Shandong University. China BioMedical Central PediatricsBMC Pediatr 2026; DOI: 10.1186/s12887-026-06954-9 AbstractBackground: Selexipag is an orally effective prostacyclin receptor agonist that has been approved for treating pulmonary arterial hypertension (PAH) in adults but is still used off-label

Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children Read More »

Sotatercept in Children with Pulmonary Hypertension-A Narrative Review

Johanna Schulz, Veronika C. Stark, Lars Harbaum, Rainer Kozlik-Feldmann, Thomas S. Mir, Fridrike Stute, Jakob OlfeUniversity Heart & Vascular Center Hamburg. University Medical Centre Hamburg-Eppendorf Hamburg.Germany ChildrenChildren 2026; 13: DOI: 10.3390/children13040465 AbstractBackground/objectives: Pulmonary arterial hypertension (PAH) is a rare but life-threatening disease that presents particular therapeutic challenges in children. It is characterized by pulmonary vasoconstriction and vascular

Sotatercept in Children with Pulmonary Hypertension-A Narrative Review Read More »

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children

Kaushik Parvathaneni, Justin J. Kochanski, Megha D. Tandel, Esther Liu, Alisa Arunamata, Jeffrey A. Feinstein, Rachel K. HopperStanford University School of Medicine and Stanford University.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70304 AbstractUse of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children Read More »

Early Results of Sotatercept Treatment in Patients With Severe Pulmonary Hypertension and a Potts Shunt

Manish A. Aggarwal, Kelly Merrill, Delphine Yung, R. Mark GradyWashington University and St Louis Children’s Hospital. University of Washington and Seattle Children’s Hospital.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70296 AbstractTwelve patients with severe pulmonary hypertension (PH) who had a pulmonary artery-to-descending aorta (Potts) shunt were treated with the novel PH drug sotatercept for an

Early Results of Sotatercept Treatment in Patients With Severe Pulmonary Hypertension and a Potts Shunt Read More »

Sildenafil for bronchopulmonary dysplasia-associated pulmonary hypertension: A systematic search and narrative synthesis

Yoshinori Katayama, Katsuya Hirata, Yutaka Nishimura, Atsuko, Nakahari, Mami Takeoka, Masahiko Watanabe, Tetsuya Isayama, Japan Evidence Based NeonatologyTakatsuki General Hospital. Osaka Women’s and Children’s Hospital. Hiroshima City Hiroshima Citizens Hospital. Jichi Medical University Saitama Medical Center. Mie University Graduate School of Medicine. National Center for Child Health and Development.Japan Pediatrics InternationalPediatr Int 2026; 68: DOI: 10.1111/ped.70385

Sildenafil for bronchopulmonary dysplasia-associated pulmonary hypertension: A systematic search and narrative synthesis Read More »

Postnatal Steroids in Preterm Infants: A Narrative Review Series-Part 2: Cardiovascular Impacts

Phoenix Plessas-Azurduy, Anie Lapointe, Punnanee Wutthigate, Sarah Spénard, Andréanne Villeneuve, Audrey Hébert, Eilon Shany, Justin Richardson, Neta Geva, Wadi Mawad, Tiscar Cavallé-Garrido, Marc Beltempo, Wissam Shalish, Guilherme Sant’Anna, Gabriel AltMcGill University. Université de Montréal, CHU Sainte-Justine. Mahidol University. Montreal Children’s Hospital. CHU de Québec and Laval University. Saban Children’s Hospital and Soroka Medical Center. Ben

Postnatal Steroids in Preterm Infants: A Narrative Review Series-Part 2: Cardiovascular Impacts Read More »

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial

Keimei Yoshida, Kazuya Hosokawa, Takahiro Hiraide, Satoshi Akagi, Kentaro Ejiri, Yu Taniguchi, Shiro Adachi, Takumi Inami, Naohiko Nakanishi, Masaharu Kataoka, Taijyu Satoh, Shunsuke Tatebe, Toshiro Shinke, Hideshi Tomita, Yusuke Akazawa, Takashi Higaki, Koshiro Tagawa, Ayako Ishikita, Soshun Asakawa, Kohtaro AbeKyushu University and Kyushu University Hospital. Keio University School of Medicine. Okayama University. Kobe University Hospital.

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial Read More »

Sotatercept in Patients With Eisenmenger Syndrome

Oktay Tutarel, Oliver Miera, Felix BergerDeutsches Herzzentrum der Charité, Freie Universität Berlin and Humboldt-Universität zu Berlin.Germany Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70283 AbstractEisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH,

Sotatercept in Patients With Eisenmenger Syndrome Read More »

Scroll to Top